Details for Patent: 7,807,689
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Which drugs does patent 7,807,689 protect, and when does it expire?
Patent 7,807,689 protects KAZANO, NESINA, and OSENI, and is included in three NDAs.
This patent has fifty-eight patent family members in thirty-five countries.
Summary for Patent: 7,807,689
| Title: | Dipeptidyl peptidase inhibitors |
| Abstract: | The present invention provides a compound of the formula: ##STR00001## or stereoisomers or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, articles of manufacture comprising the same, and methods of using the same. |
| Inventor(s): | Zhang; Zhiyuan (San Diego, CA), Elder; Bruce J. (Wynantskill, NY), Isbester; Paul K. (Castleton, NY), Palmer; Grant J. (Clifton Park, NY), Ulysse; Luckner G. (Albany, NY) |
| Assignee: | Takeda Pharmaceutical Company Limited (Osaka, JP) |
| Application Number: | 11/080,992 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,807,689 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Formulation; Dosage form; Delivery; Use; |
Drugs Protected by US Patent 7,807,689
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | KAZANO | alogliptin benzoate; metformin hydrochloride | TABLET;ORAL | 203414-002 | Jan 25, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Sign Up | ||
| Takeda Pharms Usa | KAZANO | alogliptin benzoate; metformin hydrochloride | TABLET;ORAL | 203414-001 | Jan 25, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Sign Up | ||
| Takeda Pharms Usa | NESINA | alogliptin benzoate | TABLET;ORAL | 022271-001 | Jan 25, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Sign Up | ||
| Takeda Pharms Usa | NESINA | alogliptin benzoate | TABLET;ORAL | 022271-002 | Jan 25, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Sign Up | ||
| Takeda Pharms Usa | NESINA | alogliptin benzoate | TABLET;ORAL | 022271-003 | Jan 25, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Sign Up | ||
| Takeda Pharms Usa | OSENI | alogliptin benzoate; pioglitazone hydrochloride | TABLET;ORAL | 022426-004 | Jan 25, 2013 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,807,689
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 048055 | ⤷ Sign Up | |||
| Argentina | 103423 | ⤷ Sign Up | |||
| Austria | 401320 | ⤷ Sign Up | |||
| Australia | 2004318013 | ⤷ Sign Up | |||
| Brazil | PI0418639 | ⤷ Sign Up | |||
| Canada | 2559302 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
